In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Sacubitril/Valsartan use in a real world experience: data from a large single-center population of heart failure patients with reduced ejection fraction

Session Poster Session 2

Speaker Massimo Mapelli

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Pharmacotherapy
  • Session type : Poster Session

Authors : M Mapelli (Milan,IT), E Salvioni (Milan,IT), F De Martino (Milan,IT), I Mattavelli (Milan,IT), P Gugliandolo (Milan,IT), C Vignati (Milan,IT), A Magini (Milan,IT), S Rovai (Siena,IT), S Paolillo (Naples,IT), PG Agostoni (Milan,IT)

M Mapelli1 , E Salvioni1 , F De Martino1 , I Mattavelli1 , P Gugliandolo1 , C Vignati1 , A Magini1 , S Rovai2 , S Paolillo3 , PG Agostoni1 , 1Cardiology Center Monzino IRCCS - Milan - Italy , 2University of Siena - Siena - Italy , 3Federico II University Hospital - Naples - Italy ,

Chronic Heart Failure: Pharmacotherapy

Background: Sacubitril/Valsartan has emerged as a novel therapy in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF), showing a lower cardiovascular mortality and HF hospitalization rates compared to standard therapy. Although the recent widespread use of Sacubitril/Valsartan, real life data are still lacking.
Methods: We performed a retrospective analysis of 201 monocentric patients with HFrEF, who started Sacubitril/Valsartan between September 2016 and December 2018 and followed at our HF ambulatory.We collected demographic data, clinical history with ongoing medications, baseline clinical characteristics and follow up (i.e. period of treatment until last contact with the hospital or by telephone call) about tolerated dose of Sacubitril/Valsartan, interruption of treatment, hospitalization for HF, deaths.
Results: Baseline characteristics of our population and of PARADIGM trial are presented in Tab. 1 and Fig.1A. One hundred and five patients also performed a cardiopulmonary exercise test before starting treatment, showing a mean peak VO2 of 14.9 ± 4.7 ml/min/kg (60 ± 17 % of predicted), with VE/VCO2 slope of 34.3±8.2, VO2/work of 9.4±1.5. During follow up (268 ±185 days) 36 patients had hospitalization for HF, while 20 patients interrupted treatment with Sacubitril/Valsartan (7 hypotension, 5 renal insufficiency, 1 angioedema, 7 not known/patient decision) and 9 deceased. Dose administered at baseline and at the end of follow-up is reported in Fig. 1B.
Conclusions: Compared to PARADIGM trial, our real-life population has similar characteristics and HF gravity. For clinical reasons during follow up only 31% reached the maximum dose. In future more studies are needed to analyze the prognostic impact of low vs. higher doses.





n (%)

Age (years)







Female sex

42 (21%)

879 (21%)


198 (99%)

2781 (66%)

BMI (kg/m2)







SBP (mmHg)








130 (65%)

2998 (72%)


71 (35%)

969 (23%)

Ischemic Etiology

109 (54%)

2506 (60%)


84 (42%)

623 (15%)


57 (28%)

292 (7%)

Baseline charachteristics compared to PARADIGM trial

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are